Neurologische Klinik und Poliklinik
Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Document Type
- Journal article (21)
Language
- English (21)
Keywords
- ischemic stroke (6)
- mechanical thrombectomy (3)
- neutrophils (3)
- thrombo-inflammation (3)
- acute ischemic stroke (2)
- cognitive impairment (2)
- immunohistochemistry (2)
- ischemic penumbra (2)
- middle cerebral artery occlusion (2)
- stroke (2)
Institute
- Neurologische Klinik und Poliklinik (21)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (18)
- Rudolf-Virchow-Zentrum (6)
- Institut für Experimentelle Biomedizin (4)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (3)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (2)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Medizinische Klinik und Poliklinik I (2)
- Comprehensive Cancer Center Mainfranken (1)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (1)
- Medizinische Klinik und Poliklinik II (1)
- Physikalisches Institut (1)
Sonstige beteiligte Institutionen
Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
(2023)
Background
Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively.
Case presentation
We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.
Conclusion
Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.